{"input_url":"https://insilico.com/news/prfc6c0d56cc3e2211e1d0-ism1354-gipr-antagonist","gnews_decode":"https://insilico.com/news/prfc6c0d56cc3e2211e1d0-ism1354-gipr-antagonist","http_status":200,"final_url":"https://insilico.com/news/prfc6c0d56cc3e2211e1d0-ism1354-gipr-antagonist","html_length":47947,"trafilatura_result":"ok","text_length":10106,"text_preview":"As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has become the latest Top Drug, underscoring the industry's momen","verdict":"OK"}